fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Colesevelam hydrochloride

All products: listing conditions apply

Colesevelam · PIN 09858334 · 625 mg · tablet

Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.

No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp

Check Health Canada brand search
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Colesevelam · DIN 09858334 Manufacturer: Glenmark Pharmaceuticals Canada Inc.; listing date 2024-04-30 No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN. Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Re-check Health Canada status and shortages (live)

Colesevelam: Formulary list price $0.59 per unit (the source does not state the unit; exact figure $0.5931). What the ministry pays, not the patient.

Ministry pays: $0.5931 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Ontario PIN; see Health Canada brand lookup · Verify on the e-Formulary ↗ (DIN 09858334)

Source record
DIN 09858334: Colesevelam Raw flags: chronicUseMed=Y, sec3c=Y Item: 240600077; group id 300; item number 0654; lccId None; manufacturer id GLP Source form: Tab; strength: 625mg Recorded listing: Temporary benefit (shortage substitute); chronic-use medication (100-day supply rule, dispensing-fee limit) Source prices (unrounded): $0.5931; ministry $0.5931 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=09858334 Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp Therapeutic Notes (formulary) Colesevelam Hydrochloride is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Frederickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients: . who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone, or . who are unable to tolerate a statin.
Shortage status: not checked (no credentials)
Other drugs in the same formulary class (24:06 Antilipemic Drugs) and how they are covered

Matched class: 24:06 Antilipemic Drugs

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM, ATORVASTATIN CALCIUM, BEZAFIBRATE, ROSUVASTATIN CALCIUM Some products covered without a code (check the product listing): CHOLESTYRAMINE RESIN, FENOFIBRATE, FLUVASTATIN SODIUM, GEMFIBROZIL, LOVASTATIN, PRAVASTATIN SODIUM, SIMVASTATIN 24:00 CARDIOVASCULAR DRUGS

INCLISIRAN

· 1 products · Limited Use, codes 732 · strengths: 284mg/1.5mL · Inj Sol-1.5mL Pref Syr Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:00 24:06 Antilipemic Drugs

AMLODIPINE BESYLATE & ATORVASTATIN CALCIUM

· 24 products · General benefit · strengths: 5mg & 10mg, 5mg & 20mg, 5mg & 40mg, 5mg & 80mg, 10mg & 10mg, 10mg & 20mg, 10mg & 40mg, 10mg & 80mg · Tab

ATORVASTATIN CALCIUM

· 99 products · General benefit · strengths: 10mg, 20mg, 40mg, 80mg · Tab

BEZAFIBRATE

· 2 products · General benefit · strengths: 400mg · SR Tab

CHOLESTYRAMINE RESIN

· 4 products · Listed, not a benefit (1), General benefit (3) · strengths: · Oral Pd-Pouch Pk

FENOFIBRATE

· 16 products · Listed, not a benefit (2), General benefit (9), Off-Formulary Interchangeable, not an ODB benefit (5) · strengths: 100mg, 67mg, 200mg, 160mg, 48mg, 145mg · Cap, Tab

FLUVASTATIN SODIUM

· 5 products · Listed, not a benefit (2), General benefit (3) · strengths: 20mg, 40mg, 80mg · Cap, ER Tab

GEMFIBROZIL

· 6 products · Listed, not a benefit (1), General benefit (2), Off-Formulary Interchangeable, not an ODB benefit (3) · strengths: 300mg, 600mg · Cap, Tab

LOVASTATIN

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 20mg, 40mg · Tab

PRAVASTATIN SODIUM

· 57 products · Listed, not a benefit (3), General benefit (54) · strengths: 10mg, 20mg, 40mg · Tab

ROSUVASTATIN CALCIUM

· 84 products · General benefit · strengths: 5mg, 10mg, 20mg, 40mg · Tab

SIMVASTATIN

· 73 products · Listed, not a benefit (5), General benefit (68) · strengths: 5mg, 10mg, 20mg, 40mg, 80mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 24:06 and 4 more
Full class listing Related classes: 24:04 Cardiac Drugs, 24:08 Hypotensive Drugs (For Diuretics See 40:28), 24:12 Vasodilating Drugs, 24:32 Renin-Angiotensin Aldosterone Inhibitors Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE LODALIS (colesevelam) is indicated for the reduction of cholesterol blood level in patients with hypercholesterolemia (Fredrickson Type IIa) as an adjunct to diet and lifestyle changes, when the response to these measures has been inadequate, in patients:  who are not adequately controlled with an HMG-CoA reductase inhibitor (statin) alone, or  who are unable to tolerate a statin. Limitations of Use LODALIS (colesevelam) has not been studied in Fredrickson Type I, IIb, III, IV and V dyslipidemias. Geriatrics (≥65 years of age) There is no need for dose adjustment when LODALIS is administered to elderly patients. Pediatrics (<18 years of age) The safety and efficacy of LODALIS have not been established in children and adolescent patients; therefore, the use of LODALIS in these patient populations is not recommended. Pr LODALISTM Product Monograph Page 3 of 31 https://pdf.hres.ca/dpd_pm/00059185.PDF PM date: December 4, 2020 Source product: LODALIS; DIN 02373955; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.